Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golidocitinib plus steroids as first-line therapy for high-risk chronic graft-versus-host disease
ChiCTR2500108541Phase 4Not yet recruiting
- Sponsor
- Xinqiao Hospital
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of golidocitinib in chronic graft-versus-host disease (cGVHD), sponsored by Xinqiao Hospital. Primary endpoint: Overall response rate after 3 months of treatment. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
golidocitinib
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on ChiCTR2500108541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108541.